Search
Menu
Home
HTB
2021
November
HTB
November 2021
Contents
Editorial
HTB: no. 11 – plus HIV and COVID-19 (Nov/Dec 2021)
IAS review on HIV cure research: A global scientific strategy to cure HIV (2021)
Conference reports
18th International European AIDS Conference (EACS 2021)
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
HIV-specific mental health services across the EU
Antiretrovirals
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales
MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring
Other news
UK oral history project for young people who were born with HIV
COVID-19: investigational drugs
Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs
Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab
PDFs
HTB: no. 11 – plus HIV and COVID-19 (30 November 2021)
HTB RSS
Early access
HIV guidelines recommend a statin for all people older than 40: new BHIVA document
21 November 2023
Dolutegravir monotherapy still not recommended: 4-year follow up in early-treated durably suppressed participants
12 November 2023
CHAI 2023 market report: decline in HIV funding threatens 20 years of progress
2 November 2023
Mpox vaccines still available and recommended in the UK and US
2 November 2023
All early access reports
Current issues
November 2023
October 2023
September 2023
Back issues
Special report
Uganda report: Increase in LGBTQI+ assaults and human rights violations need urgent activist responses
1 October 2023
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage